We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Arrayit Diagnostics, Inc. Reports Results of Research Study for Ovarian Cancer Diagnostic Test
News

Arrayit Diagnostics, Inc. Reports Results of Research Study for Ovarian Cancer Diagnostic Test

Arrayit Diagnostics, Inc. Reports Results of Research Study for Ovarian Cancer Diagnostic Test
News

Arrayit Diagnostics, Inc. Reports Results of Research Study for Ovarian Cancer Diagnostic Test

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Arrayit Diagnostics, Inc. Reports Results of Research Study for Ovarian Cancer Diagnostic Test"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

In this study, OvaDx(R) recorded sensitivity of 79.7%, correctly identifying patients known to have cancer, and specificity approaching 100%, correctly identifying the healthy controls, patients known not to have cancer.

Since July of 2009, AD has operated as an independent subsidiary of Arrayit Corporation and holds all the intellectual property, licenses and development agreement assets related to the pre-symptomatic ovarian cancer diagnostic test known as OvaDx(R). On December 14th, 2011, Arrayit Corporation announced the spin-off of AD and the distribution of its 78.18% interest in AD as a stock dividend to ARYC shareholders. The record date, dividend distribution date and further details will be announced shortly.

"We continue to make additional enhancements subsequent to this pilot study that indicate improvements in the sensitivity number approaching 90%. We are working to make this diagnostic test superior to any existing test. Requiring only a finger stick of blood, this will also be the easiest test to administer," says Dr. Mark Schena, President and Chief Scientific Officer of Arrayit Corporation.

Advertisement